{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T12:01:14Z","timestamp":1765540874048,"version":"3.48.0"},"reference-count":20,"publisher":"Walter de Gruyter GmbH","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jbcpp-2019-0336_s_999_w2aab3b8d176b1b7b1aab1c14b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-Hodgkin lymphoma (NHL) is a large group of primary malignancies of solid lymphoid tissue. Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of NHL. DLBCL has an aggressive natural history but responds well to chemotherapy. The objective of this study was to review the use of chemotherapy, identify its side effects, and examine the response to chemotherapy in patients with NHL at Dr. Soetomo General Hospital.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2019-0336_s_998_w2aab3b8d176b1b7b1aab1c14b2Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was a retrospective observational study using secondary data obtained from patients\u2019 medical records from 2016 to 2018. Demographic data (age, sex), clinical characteristics, chemotherapy regimens, side effects of chemotherapy, and response to chemotherapy were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2019-0336_s_997_w2aab3b8d176b1b7b1aab1c14b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Results revealed that of the 43 patients (age ranged from 21 to 80 years) who were included in this study, the prevalence of DLBCL was higher in male patients (74%) and about 44% patients were at stage III. R-CHOP (rituximab-cyclophosphamide, doxorubicin, vincristine\/oncovin, prednisone) (53%) was the most used chemotherapy regimen in this study. A total of 65% of patients showed good responses and 35% showed no response to the therapy. The most common side effect was myelosuppression, including 25% and 8% of the patients having anemia and leukopenia, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2019-0336_s_996_w2aab3b8d176b1b7b1aab1c14b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>R-CHOP is the most used regimen. Most of patients with NHL have a complete response and the predominant side effect is anemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jbcpp-2019-0336","type":"journal-article","created":{"date-parts":[[2020,1,12]],"date-time":"2020-01-12T04:11:12Z","timestamp":1578802272000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation to the chemotherapy use in patients with diffuse large B-cell lymphoma"],"prefix":"10.1515","volume":"30","author":[{"given":"Dirani","family":"Dirani","sequence":"first","affiliation":[{"name":"Universitas Airlangga, Department of Clinical Pharmacy, Faculty of Pharmacy , Campus C UNAIR, Mulyorejo Surabaya - 60115 , Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Suharjono","sequence":"additional","affiliation":[{"name":"Universitas Airlangga, Department of Clinical Pharmacy, Faculty of Pharmacy , Campus C UNAIR, Mulyorejo Surabaya - 60115 , Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Made","family":"Sedana","sequence":"additional","affiliation":[{"name":"Dr. Soetomo General Hospital , Surabaya, Jawa Timur , Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siti","family":"Wahyuni","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Dr. Soetomo General Hospital , Surabaya , Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrismawan","family":"Ardianto","sequence":"additional","affiliation":[{"name":"Universitas Airlangga, Department of Clinical Pharmacy, Faculty of Pharmacy , Campus C UNAIR, Mulyorejo Surabaya - 60115 , Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Alderman","sequence":"additional","affiliation":[{"name":"Universitas Airlangga, Department of Clinical Pharmacy, Faculty of Pharmacy , Campus C UNAIR, Mulyorejo Surabaya - 60115 , Indonesia"},{"name":"School of Pharmacy and Medical Sciences, University of South Australia , Adelaide , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"key":"2025121209161525890_j_jbcpp-2019-0336_ref_001_w2aab3b8d176b1b7b1ab2b2b1Aa","unstructured":"Fausel C. Chapter 90: Malignant Lhymphomas. In: Chishol-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, Rotschafer J, et al., editors. Pharmacotherapy principle and practice. USA: The McGraw-Hill Education, 2008:1371\u201384."},{"key":"2025121209161525890_j_jbcpp-2019-0336_ref_002_w2aab3b8d176b1b7b1ab2b2b2Aa","unstructured":"Hecht KA, Liewer SE. Malignant Lymphomas. In: Chisholm-Burns MA, Schwinghammer TL, Wells BG, Malone PM, Kolesar JM, Dipiro JT, editors. Pharmacotherapy principles and practice, 4th ed. New York: The McGraw-Hill Education, 2016:1433\u201359."},{"key":"2025121209161525890_j_jbcpp-2019-0336_ref_003_w2aab3b8d176b1b7b1ab2b2b3Aa","unstructured":"American Cancer Society. 2018. Chemotherapy for non-Hodgkin lymphoma. American Cancer Society. Available at: https:\/\/www.cancer.org\/cancer\/non-hodgkin-lymphoma.html. Accessed: 28 Oct 2018."},{"key":"2025121209161525890_j_jbcpp-2019-0336_ref_004_w2aab3b8d176b1b7b1ab2b2b4Aa","unstructured":"Dark GG. The global burden of cancer. In: Dark GG, editor. Oncology at a glance, 1st ed. UK: John Wiley & Sons, Ltd, 2013:10\u201311."},{"key":"2025121209161525890_j_jbcpp-2019-0336_ref_005_w2aab3b8d176b1b7b1ab2b2b5Aa","unstructured":"Kementerian Kesehatan Republik Indonesia. Data dan Kondisi Penyakit Limfoma di Indonesia. Jakarta: Kementerian Kesehatan Republik Indonesia, 2015:1\u20134."},{"key":"2025121209161525890_j_jbcpp-2019-0336_ref_006_w2aab3b8d176b1b7b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Reksodiputro AH. Multicentre epidemiology and survival study of B cell non Hodgkin lymphoma patients in Indonesia. J Blood Disorder Transfusion 2015;6:1\u20135.","DOI":"10.4172\/2155-9864.1000257"},{"key":"2025121209161525890_j_jbcpp-2019-0336_ref_007_w2aab3b8d176b1b7b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Jacobson JO, Polovich M, Gilmore TR, Schulmeister L, Esper P, LeFebvre KB, et al. Revisions to the 2009 American Society of Clinical Oncology\/Oncology Nursing Society Chemotherapy Administration Safety Standards: expanding the scope to include inpatient settings. Oncol Nurs Forum 2012;39:31\u20138.","DOI":"10.1188\/12.ONF.31-38"},{"key":"2025121209161525890_j_jbcpp-2019-0336_ref_008_w2aab3b8d176b1b7b1ab2b2b8Aa","unstructured":"Mansi J. Generic chemotherapy protocol guidelines. London, England: NHS South East London Cancer Network, 2013:3\u20135."},{"key":"2025121209161525890_j_jbcpp-2019-0336_ref_009_w2aab3b8d176b1b7b1ab2b2b9Aa","unstructured":"NCCN. Non-Hodgkin\u2019s Lymphomas. London, England: National Comprehensive Cancer Network, 2014:58\u201370."},{"key":"2025121209161525890_j_jbcpp-2019-0336_ref_010_w2aab3b8d176b1b7b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Castillo JJ, Ghobrial IM, Treon SP. Biology, prognosis, and therapy of Waldenstr\u00f6m macroglobulinemia. Cancer Treat Res 2015;165:177\u201396.","DOI":"10.1007\/978-3-319-13150-4_7"},{"key":"2025121209161525890_j_jbcpp-2019-0336_ref_011_w2aab3b8d176b1b7b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Ondrejka SL, Hsi ED. Pathology of B-cell lymphomas: diagnosis and biomarker discovery. Cancer Treat Res 2015;165:1\u201326.","DOI":"10.1007\/978-3-319-13150-4_2"},{"key":"2025121209161525890_j_jbcpp-2019-0336_ref_012_w2aab3b8d176b1b7b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Winkfield KM, Tsang RW, Gospodarowicz MK. Chapter 77: non-hodgkin\u2019s lymphoma. In: Winkfield KM, Tsang RW, Gospodarowicz MK, editors. Clinical radiation oncology. Philadephia: Elsevier; 2016:1524\u201346.","DOI":"10.1016\/B978-0-323-24098-7.00077-0"},{"key":"2025121209161525890_j_jbcpp-2019-0336_ref_013_w2aab3b8d176b1b7b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Jaffe ES, Pittaluga S, Anastasi J. Chapter 73: the pathologic basis for the classification of non-hodgkin and hodgkin lymphomas. In: Hoffman R, Benz EJ, Silberstein LE, Heslop H, Weitz J, Anastasi J, editors. Hematology: diagnosis and treatment. Philadephia: Elsevier, 2018:1187\u2013203.","DOI":"10.1016\/B978-0-323-35762-3.00073-1"},{"key":"2025121209161525890_j_jbcpp-2019-0336_ref_014_w2aab3b8d176b1b7b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Rubenstein JL, Gupta NK, Mannis GN, LaMarre AK, Treseler P. How I treat CNS lymphoma. American Society of Hematology. Blood 2013;122:3061\u20137.","DOI":"10.1182\/blood-2013-06-453084"},{"key":"2025121209161525890_j_jbcpp-2019-0336_ref_015_w2aab3b8d176b1b7b1ab2b2c15Aa","unstructured":"ASCO. 2015. Understanding Targeted Therapy. American Society of Clinical Oncology. Available at: www.cancer.net\/navigating-cancer-care\/hoe-cancertreated\/personalized-and-targeted-theraphies\/understanding-targeted-therapy. Accessed: 30 Oct 2018."},{"key":"2025121209161525890_j_jbcpp-2019-0336_ref_016_w2aab3b8d176b1b7b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Chiu BC, Hou N. Epidemiology and etiology of non-Hodgkin lymphoma. Cancer Treat Res 2015;165:1\u201326.","DOI":"10.1007\/978-3-319-13150-4_1"},{"key":"2025121209161525890_j_jbcpp-2019-0336_ref_017_w2aab3b8d176b1b7b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Salma RS, Bintoro UY, Sedana MP. CHOP and R-CHOP therapeutic responses in non-Hodgkin lymphoma patients in Dr. Soetomo General Hospital Surabaya. Biomol Health Sci J 2018;2:93\u20136.","DOI":"10.20473\/bhsj.v1i2.9244"},{"key":"2025121209161525890_j_jbcpp-2019-0336_ref_018_w2aab3b8d176b1b7b1ab2b2c18Aa","unstructured":"BCCA. BC cancer agency cancer drug manual, doxorubicin. London, England: BC Cancer Agency, 2017:1\u20139."},{"key":"2025121209161525890_j_jbcpp-2019-0336_ref_019_w2aab3b8d176b1b7b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendation for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059\u201367.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"2025121209161525890_j_jbcpp-2019-0336_ref_020_w2aab3b8d176b1b7b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Gordon KA, Tosti A. Alopecia: evaluation and treatment. Clin Cosmet Investig Dermatol 2011;4:101\u20136.","DOI":"10.2147\/CCID.S10182"}],"container-title":["Journal of Basic and Clinical Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/jbcpp\/30\/6\/article-20190336.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2019-0336\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2019-0336\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T11:56:23Z","timestamp":1765540583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2019-0336\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,2,7]]},"published-print":{"date-parts":[[2019,11,26]]}},"alternative-id":["10.1515\/jbcpp-2019-0336"],"URL":"https:\/\/doi.org\/10.1515\/jbcpp-2019-0336","relation":{},"ISSN":["2191-0286"],"issn-type":[{"type":"electronic","value":"2191-0286"}],"subject":[],"published":{"date-parts":[[2019,11,1]]},"article-number":"20190336"}}